Veracyte, Inc.
VCYTHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframePart of the healthcare sector, Veracyte, Inc. (VCYT) is listed under Diagnostics & Research. At a $3.85B market cap, Veracyte, Inc. ranks as a mid-cap company within healthcare. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
Market Cap
$3.85B
Beta
1.95
P/E (TTM)
32.83
P/E (Fwd)
24.67
EPS (TTM)
$1.46
EPS (Fwd)
$1.94
ROE
8.8%
ROA
4.1%
Cash
$485.2M
Total Debt
$40.1M
Free CF
$106.2M
52W Change
30.5%
Annual Financials
Cash vs Debt
Where VCYT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, VCYT finished 0.73% below its 150-day moving average ($44.12) and 2.82% above its 200-day moving average ($42.60). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VCYT overbought or oversold?
At the October 20, 2026 close, VCYT's RSI(14) was 43.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $485.2M in cash comfortably exceeding the $40.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $106.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 8.8%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $296.5M (2022) to $517.1M (2025), reflecting a 74% increase over the period.
With a beta above 1.5, VCYT tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, VCYT has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Veracyte, Inc.'s trajectory.